David Nierengarten

Stock Analyst at Wedbush

(4.42)
# 311
Out of 5,152 analysts
215
Total ratings
53.98%
Success rate
18.38%
Average return

Stocks Rated by David Nierengarten

TScan Therapeutics
Mar 5, 2026
Maintains: Outperform
Price Target: $4$5
Current: $1.08
Upside: +362.96%
Apogee Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $90$95
Current: $72.31
Upside: +31.38%
Beam Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $57$65
Current: $27.44
Upside: +136.88%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Outperform
Price Target: $50$53
Current: $47.27
Upside: +12.12%
ORIC Pharmaceuticals
Feb 24, 2026
Reiterates: Outperform
Price Target: $20
Current: $13.51
Upside: +48.04%
ABIVAX Société Anonyme
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $116.77
Upside: -5.80%
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $110$88
Current: $61.10
Upside: +44.03%
Nuvation Bio
Feb 10, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.74
Upside: +132.07%
Perspective Therapeutics
Jan 30, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.27
Upside: +108.73%
Cogent Biosciences
Jan 21, 2026
Reiterates: Outperform
Price Target: $55
Current: $37.02
Upside: +48.57%
Reiterates: Outperform
Price Target: $31
Current: $22.52
Upside: +37.66%
Reiterates: Neutral
Price Target: $18
Current: $13.42
Upside: +34.13%
Reiterates: Outperform
Price Target: $1,000
Current: $749.56
Upside: +33.41%
Reiterates: Outperform
Price Target: $30
Current: $18.54
Upside: +61.81%
Reiterates: Outperform
Price Target: $25
Current: $10.17
Upside: +145.82%
Maintains: Neutral
Price Target: $9$7
Current: $13.82
Upside: -49.35%
Upgrades: Outperform
Price Target: $5$7
Current: $1.45
Upside: +382.76%
Reiterates: Outperform
Price Target: $115
Current: $102.67
Upside: +12.01%
Initiates: Outperform
Price Target: $4
Current: $4.73
Upside: -15.43%
Reiterates: Outperform
Price Target: $26
Current: $12.74
Upside: +104.08%
Reiterates: Outperform
Price Target: $22
Current: $6.87
Upside: +220.23%
Reiterates: Neutral
Price Target: $8
Current: $15.05
Upside: -46.84%
Downgrades: Neutral
Price Target: $80$20
Current: $21.31
Upside: -6.15%
Maintains: Outperform
Price Target: $40
Current: $60.55
Upside: -33.94%
Maintains: Outperform
Price Target: $40$47
Current: $47.43
Upside: -0.91%
Initiates: Outperform
Price Target: $40
Current: $34.99
Upside: +14.32%
Initiates: Outperform
Price Target: $45
Current: $41.00
Upside: +9.76%
Initiates: Outperform
Price Target: $18
Current: $5.46
Upside: +229.67%
Reiterates: Outperform
Price Target: $12
Current: $4.12
Upside: +191.26%
Maintains: Equal-Weight
Price Target: $1,400$500
Current: $2.28
Upside: +21,829.82%
Maintains: Neutral
Price Target: $105$60
Current: $9.15
Upside: +555.74%
Maintains: Outperform
Price Target: $11$19
Current: $8.20
Upside: +131.71%
Maintains: Outperform
Price Target: $71$75
Current: $21.80
Upside: +244.04%
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $4.13
Upside: -
Downgrades: Neutral
Price Target: n/a
Current: $9.86
Upside: -